Read more Novartis AG stories on Newserhttp://www.newser.com/taggrid/20407/novartis-ag.html2009 - Newseren-usNewser Feed GeneratorTue, 24 Nov 2009 8:25:20 CSThttp://www.newser.com/story/50598/novartis-acquires-plavix-rival.html?utm_source=syn&utm_medium=rss&utm_campaign=tagNovartis AG will pay a San Francisco biopharmaceutical company $75 million—with the potential for an additional $500 million—for the worldwide rights to an experimental anticlotting drug the Swiss drug firm hopes will rival Plavix, reports the Wall Street Journal. Market leader Plavix rang up $8.22 billion in...http://www.newser.com/story/50598/novartis-acquires-plavix-rival.html?utm_source=syn&utm_medium=rss&utm_campaign=tagThu, 12 Feb 2009 8:22:53 CSThttp://www.newser.com/story/28891/bone-drug-reduces-breast-cancer-relapse.html?utm_source=syn&utm_medium=rss&utm_campaign=tagA drug designed to protect cancer patients' bones also renders breast cancer relapses less likely, a new study says. Funded in part by the drug's maker, Novartis, researchers found that even two injections of Zometa a year cut tumor recurrence by 35% in more than 1,800 pre-menopausal women.http://www.newser.com/story/28891/bone-drug-reduces-breast-cancer-relapse.html?utm_source=syn&utm_medium=rss&utm_campaign=tagSat, 31 May 2008 19:21:18 CDThttp://www.newser.com/story/21263/drug-therapy-cuts-risk-of-breast-cancer-relapse.html?utm_source=syn&utm_medium=rss&utm_campaign=tagNew research shows that women can cut the risk of breast cancer recurring years later by taking certain drugs, the Washington Post reports. Studies show that the drugs, known as aromatase inhibitors, sharply reduced the risk of cancer's return after women had finished their regimen of the widely used tamoxifen....http://www.newser.com/story/21263/drug-therapy-cuts-risk-of-breast-cancer-relapse.html?utm_source=syn&utm_medium=rss&utm_campaign=tagTue, 11 Mar 2008 7:16:21 CDThttp://www.newser.com/story/15904/beefed-up-rd-slows-drug-approval.html?utm_source=syn&utm_medium=rss&utm_campaign=tagThe FDA approved only 19 new drugs in 2007, the lowest total in 24 years. Bloomberg takes a look at the reasons. Some drug companies accuse the FDA of setting the bar higher for drug approvals, a charge the agency denies. Many, however, say the issue lies with big pharma...http://www.newser.com/story/15904/beefed-up-rd-slows-drug-approval.html?utm_source=syn&utm_medium=rss&utm_campaign=tagTue, 08 Jan 2008 17:45:48 CST